Disease or Syndrome – Page 2

Viking Therapeutics to Highlight VK2735 Clinical Data at ObesityWeek 2025

5 days ago talkbio0Tagged Clinical Data, Clinical Trials, GLP-1/GIP Dual Agonist, Metabolic Syndrome X, Obesity, ObesityWeek 2025, Prediabetes syndrome, VANQUISH-1, venture, Viking Therapeutics, VK2735

Viking Therapeutics; VK2735; ObesityWeek 2025; VENTURE trial; VANQUISH-1 trial; GLP-1/GIP dual agonist; clinical data; obesity; prediabetes; metabolic syndrome

AI-Designed Drug AH-001 Completes U.S. Phase I Trial, Demonstrating Excellent Safety and Tolerability

5 days ago talkbio0Tagged AH 001, AI-designed drug, Alopecia, Androgenetic Alopecia, AnHorn Medicines, Generative AI, Phase I Clinical Trials, protein degrader, Safety, tolerability

AH-001; AI-designed drug; Phase I clinical trial; safety; tolerability; androgenetic alopecia; protein degrader; AnHorn Medicines; generative AI; hair loss

Novo Nordisk Launches Surprise Bid for Metsera, Topping Pfizer Offer; Pfizer Alleges Move May Violate Antitrust Law

5 days ago talkbio0Tagged Acquisition, Antitrust, bidding war, Metsera, Novo Nordisk, Obesity, Pfizer, Twice a day, Unsolicited Adverse Event, Weight-Loss Agents

Novo Nordisk; Metsera; Pfizer; acquisition; bidding war; obesity; antitrust; unsolicited bid; weight-loss drugs

Roche Signs $1B Licensing Deal with Qyuns Therapeutics for Preclinical COPD Bispecific Antibody

5 days ago talkbio0Tagged Antibodies, Bispecific, biobucks, China, COPD, IL33 protein, human, Preclinical, Qyuns Therapeutics, Respiration Disorders, Roche (company), TSLP gene

Roche; Qyuns Therapeutics; bispecific antibody; COPD; preclinical; TSLP; IL-33; China biotech; biobucks; respiratory disease

No Recent News on BridgeBio’s Thyroid Disorder Phase 3 Win

6 days ago talkbio0Tagged BridgeBio, Infrequent, Phase 3, Thyroid Diseases

BridgeBio; Phase 3; Rare Diseases; Thyroid Disorder

Eli Lilly and Nvidia to Build Pharma’s Largest AI Supercomputer for Drug Discovery

6 days ago talkbio0Tagged Artificial Intelligence, biomedical foundation models, Blackwell Ultra GPU, Clinical Trials, Drug Discovery, Drug Industry, eli lilly, high-performance computing, NVIDIA, supercomputer

Eli Lilly; Nvidia; supercomputer; AI; drug discovery; Blackwell Ultra GPU; clinical trials; biomedical foundation models; pharmaceutical industry; high-performance computing

BioMarin Plans to Divest Hemophilia Gene Therapy Roctavian Amid Strategic Refocus

6 days ago talkbio0Tagged BioMarin, Divestment, gene therapy, Hemophilia A, out-licensing, portfolio strategy, Roctavian

BioMarin; Roctavian; hemophilia A; gene therapy; divestment; out-licensing; portfolio strategy; third quarter 2025; revenue challenge

Intellia Pauses Two CRISPR Trials After Severe Liver Toxicity Hospitalizes Patient

1 week ago talkbio0Tagged Clustered Regularly Interspaced Short Palindromic Repeats, Gene Modification, Hospitalization, Intellia, Liver, Pauses, Phase 3 Clinical Trials, Safety, Senile cardiac amyloidosis, Toxicity aspects

Intellia Therapeutics; CRISPR; transthyretin amyloidosis; Phase III trials; gene editing; liver toxicity; patient hospitalization; safety pause

BridgeBio Shifts Filing Plans After Phase 3 Success in Rare Disease Drug BBP-418

1 week ago talkbio0Tagged Acoramidis, Approved, BBP-418, Biological Markers, BridgeBio, commercial, disease drug, File (record), Infrequent, Limb-girdle muscular dystrophy type 2A, NDA, New Drug Application, Phase 3 success, Ribitol, United States Food and Drug Administration

BridgeBio; BBP-418; Phase 3 success; limb-girdle muscular dystrophy type 2I/R9; FDA filing; rare disease drug; NDA (New Drug Application); ribitol; full approval; biomarker; acoramidis; commercial strategy

OpenAI Collaborates with Thermo Fisher and Lundbeck to Enhance Pharma Research

1 week ago talkbio0Tagged DNA Integration, Lundbeck, OpenAI, Pharma, Thermo Fisher

OpenAI; Thermo Fisher; Lundbeck; Pharma; AI Integration